drugset / Trial / NCT06012695
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.
Timeline
- Start
- 2023-08-11
- Primary completion
- 2028-05-30
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBM-BMX | Small molecule | 100 mg | Oral |
| Background | Temozolomide | Small molecule | 75 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |